secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001104659-26-032077
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio FY2025 net loss $99.4M; raised $144M in Feb 2026; tibulizumab data on track
--------------------------------------------------------------------------------

- Net loss attributable to Class A shareholders $99.4M ($1.06/share) vs $45.4M ($0.60) in 2024.
- Cash and equivalents $109.4M at Dec 31, 2025; Feb 2026 offering raised ~$144M gross.
- R&D expenses $42.1M, up 73% YoY, driven by Phase 2 tibulizumab programs.
- Phase 2 TibuSHIELD (HS) topline data expected Q4 2026; TibuSURE (SSc) data H1 2027.
- Appointed Sandeep Kulkarni as CEO in Jan 2026; added two board members in Feb 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465926032077/0001104659-26-032077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465926032077/tm269296d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-032077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer